PTFE monocusp valve reconstruction of the right ventricular outflow tract

Mark W. Turrentine, Ryan P. McCarthy, Palaniswamy Vijay, Kevin W. McConnell, John W. Brown

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background. Transannular patching of right ventricular outflow tract obstructive (RVOTO) defects results in pulmonary insufficiency (PI). Biologic monocusp valves (MO) can prevent acute PI but are prone to early degeneration and progressive regurgitation. Polytetrafluoroethylene (PTFE, 0.1 mm) MO leaflets demonstrated favorable characteristics in animal studies, and the technique was applied to a variety of RVOTO anomalies. Methods. From June 1990 through June 1999, 158 patients underwent either PTFE MO RVOT reconstruction (n = 115 patients; 120 implants) or nonvalved transannular repair (TA) repairs (n = 43 patients; 5 subsequent MO implants) at our institution. Standard MO construction techniques and TA repairs were utilized. Intraoperative, postoperative, and echocardiographic data with a mean interval of 2.6 years (range 6 months to 8 years) were used in retrospective fashion to compare clinical outcomes. In addition, PTFE monocusp valves beyond 6 months post-implant underwent echocardiographic analysis of MO function and durability. Results. There were 4 early (MO-3, TA-1) and no late deaths. Overall, perioperative complications were not significantly different between MO and TA groups, nor were total hospitalization days (9.1 versus 10.7, p = 0.24). However, a significant difference in intensive care unit (ICU) utilization (3.6 versus 5.8 days, p = 0.03) favored MO patients. Patients with tetralogy of Fallot (TOF) and ventricular septal defect/pulmonary atresia (VSD/PA) undergoing the MO implant demonstrated a trend toward improved survival (p = 0.08) when compared to TA repairs. Intraoperative PI was graded mild in the MO group and moderate-severe in the TA group (p = 0.003). Progressive MO regurgitation occurred (mild-moderate) but remained significantly less than the transannular patch repairs (p < 0.05). Conclusions. Utilization of a PTFE MO valve prevents short-term and significantly reduces midterm PI. It is inexpensive, easy to construct, and demonstrates no evidence of stenosis, calcification, or embolization. Despite longer cardiopulmonary bypass and ischemic times, it reduces ICU stay and, in both TOF and VSD/PA patients, decreases operative morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)871-880
Number of pages10
JournalAnnals of Thoracic Surgery
Volume73
Issue number3
DOIs
StatePublished - Mar 12 2002

Fingerprint

Polytetrafluoroethylene
Pulmonary Atresia
Lung
Tetralogy of Fallot
Ventricular Heart Septal Defects
Intensive Care Units
Cardiopulmonary Bypass
Pathologic Constriction
Hospitalization
Morbidity
Survival
Mortality

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

PTFE monocusp valve reconstruction of the right ventricular outflow tract. / Turrentine, Mark W.; McCarthy, Ryan P.; Vijay, Palaniswamy; McConnell, Kevin W.; Brown, John W.

In: Annals of Thoracic Surgery, Vol. 73, No. 3, 12.03.2002, p. 871-880.

Research output: Contribution to journalArticle

Turrentine, Mark W. ; McCarthy, Ryan P. ; Vijay, Palaniswamy ; McConnell, Kevin W. ; Brown, John W. / PTFE monocusp valve reconstruction of the right ventricular outflow tract. In: Annals of Thoracic Surgery. 2002 ; Vol. 73, No. 3. pp. 871-880.
@article{e7efca74bdb14b06876bd27e35be216e,
title = "PTFE monocusp valve reconstruction of the right ventricular outflow tract",
abstract = "Background. Transannular patching of right ventricular outflow tract obstructive (RVOTO) defects results in pulmonary insufficiency (PI). Biologic monocusp valves (MO) can prevent acute PI but are prone to early degeneration and progressive regurgitation. Polytetrafluoroethylene (PTFE, 0.1 mm) MO leaflets demonstrated favorable characteristics in animal studies, and the technique was applied to a variety of RVOTO anomalies. Methods. From June 1990 through June 1999, 158 patients underwent either PTFE MO RVOT reconstruction (n = 115 patients; 120 implants) or nonvalved transannular repair (TA) repairs (n = 43 patients; 5 subsequent MO implants) at our institution. Standard MO construction techniques and TA repairs were utilized. Intraoperative, postoperative, and echocardiographic data with a mean interval of 2.6 years (range 6 months to 8 years) were used in retrospective fashion to compare clinical outcomes. In addition, PTFE monocusp valves beyond 6 months post-implant underwent echocardiographic analysis of MO function and durability. Results. There were 4 early (MO-3, TA-1) and no late deaths. Overall, perioperative complications were not significantly different between MO and TA groups, nor were total hospitalization days (9.1 versus 10.7, p = 0.24). However, a significant difference in intensive care unit (ICU) utilization (3.6 versus 5.8 days, p = 0.03) favored MO patients. Patients with tetralogy of Fallot (TOF) and ventricular septal defect/pulmonary atresia (VSD/PA) undergoing the MO implant demonstrated a trend toward improved survival (p = 0.08) when compared to TA repairs. Intraoperative PI was graded mild in the MO group and moderate-severe in the TA group (p = 0.003). Progressive MO regurgitation occurred (mild-moderate) but remained significantly less than the transannular patch repairs (p < 0.05). Conclusions. Utilization of a PTFE MO valve prevents short-term and significantly reduces midterm PI. It is inexpensive, easy to construct, and demonstrates no evidence of stenosis, calcification, or embolization. Despite longer cardiopulmonary bypass and ischemic times, it reduces ICU stay and, in both TOF and VSD/PA patients, decreases operative morbidity and mortality.",
author = "Turrentine, {Mark W.} and McCarthy, {Ryan P.} and Palaniswamy Vijay and McConnell, {Kevin W.} and Brown, {John W.}",
year = "2002",
month = "3",
day = "12",
doi = "10.1016/S0003-4975(01)03441-5",
language = "English (US)",
volume = "73",
pages = "871--880",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - PTFE monocusp valve reconstruction of the right ventricular outflow tract

AU - Turrentine, Mark W.

AU - McCarthy, Ryan P.

AU - Vijay, Palaniswamy

AU - McConnell, Kevin W.

AU - Brown, John W.

PY - 2002/3/12

Y1 - 2002/3/12

N2 - Background. Transannular patching of right ventricular outflow tract obstructive (RVOTO) defects results in pulmonary insufficiency (PI). Biologic monocusp valves (MO) can prevent acute PI but are prone to early degeneration and progressive regurgitation. Polytetrafluoroethylene (PTFE, 0.1 mm) MO leaflets demonstrated favorable characteristics in animal studies, and the technique was applied to a variety of RVOTO anomalies. Methods. From June 1990 through June 1999, 158 patients underwent either PTFE MO RVOT reconstruction (n = 115 patients; 120 implants) or nonvalved transannular repair (TA) repairs (n = 43 patients; 5 subsequent MO implants) at our institution. Standard MO construction techniques and TA repairs were utilized. Intraoperative, postoperative, and echocardiographic data with a mean interval of 2.6 years (range 6 months to 8 years) were used in retrospective fashion to compare clinical outcomes. In addition, PTFE monocusp valves beyond 6 months post-implant underwent echocardiographic analysis of MO function and durability. Results. There were 4 early (MO-3, TA-1) and no late deaths. Overall, perioperative complications were not significantly different between MO and TA groups, nor were total hospitalization days (9.1 versus 10.7, p = 0.24). However, a significant difference in intensive care unit (ICU) utilization (3.6 versus 5.8 days, p = 0.03) favored MO patients. Patients with tetralogy of Fallot (TOF) and ventricular septal defect/pulmonary atresia (VSD/PA) undergoing the MO implant demonstrated a trend toward improved survival (p = 0.08) when compared to TA repairs. Intraoperative PI was graded mild in the MO group and moderate-severe in the TA group (p = 0.003). Progressive MO regurgitation occurred (mild-moderate) but remained significantly less than the transannular patch repairs (p < 0.05). Conclusions. Utilization of a PTFE MO valve prevents short-term and significantly reduces midterm PI. It is inexpensive, easy to construct, and demonstrates no evidence of stenosis, calcification, or embolization. Despite longer cardiopulmonary bypass and ischemic times, it reduces ICU stay and, in both TOF and VSD/PA patients, decreases operative morbidity and mortality.

AB - Background. Transannular patching of right ventricular outflow tract obstructive (RVOTO) defects results in pulmonary insufficiency (PI). Biologic monocusp valves (MO) can prevent acute PI but are prone to early degeneration and progressive regurgitation. Polytetrafluoroethylene (PTFE, 0.1 mm) MO leaflets demonstrated favorable characteristics in animal studies, and the technique was applied to a variety of RVOTO anomalies. Methods. From June 1990 through June 1999, 158 patients underwent either PTFE MO RVOT reconstruction (n = 115 patients; 120 implants) or nonvalved transannular repair (TA) repairs (n = 43 patients; 5 subsequent MO implants) at our institution. Standard MO construction techniques and TA repairs were utilized. Intraoperative, postoperative, and echocardiographic data with a mean interval of 2.6 years (range 6 months to 8 years) were used in retrospective fashion to compare clinical outcomes. In addition, PTFE monocusp valves beyond 6 months post-implant underwent echocardiographic analysis of MO function and durability. Results. There were 4 early (MO-3, TA-1) and no late deaths. Overall, perioperative complications were not significantly different between MO and TA groups, nor were total hospitalization days (9.1 versus 10.7, p = 0.24). However, a significant difference in intensive care unit (ICU) utilization (3.6 versus 5.8 days, p = 0.03) favored MO patients. Patients with tetralogy of Fallot (TOF) and ventricular septal defect/pulmonary atresia (VSD/PA) undergoing the MO implant demonstrated a trend toward improved survival (p = 0.08) when compared to TA repairs. Intraoperative PI was graded mild in the MO group and moderate-severe in the TA group (p = 0.003). Progressive MO regurgitation occurred (mild-moderate) but remained significantly less than the transannular patch repairs (p < 0.05). Conclusions. Utilization of a PTFE MO valve prevents short-term and significantly reduces midterm PI. It is inexpensive, easy to construct, and demonstrates no evidence of stenosis, calcification, or embolization. Despite longer cardiopulmonary bypass and ischemic times, it reduces ICU stay and, in both TOF and VSD/PA patients, decreases operative morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=0036189764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036189764&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(01)03441-5

DO - 10.1016/S0003-4975(01)03441-5

M3 - Article

C2 - 11899194

AN - SCOPUS:0036189764

VL - 73

SP - 871

EP - 880

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -